Complete Genome Sequence of Streptomyces olivoreticuli ATCC 31159 Which can Produce Anticancer Bestatin and Show Diverse Secondary Metabolic Potentials
- 38 Downloads
Because of its competitive inhibitor activity against aminopeptidase B, bestatin isolated from the broth of Streptomyces olivoreticuli ATCC 31159 is famous and currently used as an approved therapeutic agent for cancer and bacterial infections. It can be used alone or in combination with other antibiotics or anticancer drugs as adjuvant therapy drug for chemotherapy and radiotherapy. Due to the therapeutic importance of bestatin, mining of its biosynthetic mechanism is imperative. Genome mining, one of the bioinformatics-based approaches for the discovery of novel natural product, has been developed and applied widely. Herein, we reported the complete genome of Streptomyces olivoreticuli ATCC 31159 obtained from American Type Culture Collection (ATCC). It consists of 8,809,793 base pairs with a linear chromosome, GC content of 71.1%, 7520 protein-coding genes, 75 tRNA operons, 21 rRNA operons, 63 sRNAs. In addition, predictive analysis showed that at least 37 putative biosynthetic gene clusters (BGCs) of the secondary metabolites were obtained, 18 new BGCs with low similarity (< 25%) were included. The availability of novel and abundant gene clusters not only will provide clues for cracking the biosynthetic mechanism of bestatin, but also will provide valuable insight for mining the diverse bioactive compounds based on rational strategies.
This work was financially supported by grants from the Science & Technology Development Foundation of the University of Tianjin Municipal City: Directional excavating of the novel lantibiotics and its activities of inhibiting food spoilage (Grant No. 20170619); Innovation Team Project for Colleges and Universities in Tianjin city: Study on New Technology and Related Mechanism of Processing and Storage of Agricultural Products (Grant No. TD13-5087); National Training Program of Innovation and Entrepreneurship for Undergraduates (Grant No. 201710069036) and the Breeding Project of National Natural Science Fund of China (Grant No. 17103-60104-2017ZT010503).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no competing interests.
Research involving Human and Animal Participants
This article does not contain any studies with human participants or animals performed by any of the authors.
- 5.Umezawa H (2014) Small molecular immunomodifiers of microbial origin: fundamental and clinical studies of bestatin. Institute of Microbial Chemistry, TokyoGoogle Scholar